James Cullem Comments on Cell Signaling Technology’s Patent Portfolio

 James CullemAs the former Chief Counsel and Director of Intellectual Property & Licensing at Cell Signaling Technology, Inc., James Cullem reflects on the pivotal issuance to the company of a U.S. patent covering a vital class of Context-Independent and Motif-Specific Antibodies.

A Gathering of Experts: Hello and thank you for joining us this morning.

James Cullem: Glad to be here with you as well.

A Gathering of Experts: What does this patent and portfolio mean for Cell Signaling Technology?

James Cullem: The patents on this novel and powerful class of antibodies validates the company’s leadership role in developing and commercializing new reagents that are advancing signal transduction research to elucidate diseases like cancer.  And, of course, as a competitive market advantage, it provides the company with a highly valuable market exclusivity in leveraging this technology towards diagnostics and therapeutics development. [Read more…]

VN:F [1.9.22_1171]
Rating: 5.0/5 (2 votes cast)
VN:F [1.9.22_1171]
Rating: +1 (from 1 vote)